,,ii  #aagth ,,congress  #ast ,session  
,s4 #bdhf  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,july #bg1     
#bjba,ms4 ,warren introduced the        
following bill2 which was read twice and
 referred to the ,committee on ,armed   
,services  ,a ,,bill  ,to authorize the 
use of drugs1 vaccines1 and medical     
technologies to expand military and     
civilian access to such products and to 
improve transparency in taxpayer-funded 
biomedical research investments by the  
,department of ,defense1 and for other  
purposes4  #a4 ,short title ,this ,act  
may be cited as the ,make               
,taxpayer-,funded ,department of        
,defense ,medical ,interventions        
,affordable ,act 4  #b4 ,authorization  
of use of drugs1 vaccines1 and medical  
technologies to expand military and     
civilian access to such products  7a7   
,report and identification of products  
,not later than one year after the date 
of the enactment of this ,act1 the      
,secretary of ,defense shall submit to  

the ,committees on ,armed ,services of  
the ,senate and the ,house of           
,representatives a report on the efforts
 of the ,secretary to comply with the   
paragraph entitled1 ,licensing of       
,federally owned medical interventions  
included on page #agc of the report of  
the ,committee on ,armed ,services of   
the ,senate to accompany the ,national  
,defense ,authorization ,act for ,fiscal
 ,year #bjah 7,public ,law #aae-ia71    
which shall include the following       
information3 7#a7 ,a description of what
 steps1 if any1 the ,secretary has taken
 to comply with that paragraph4  7#b7 ,a
 complete list of the drugs1 vaccines1  
and medical technologies that1 as of the
 date of the enactment of this ,act1    
meet the requirements outlined in that  
paragraph4  7#c7 ,for each drug1        
vaccine1 or medical technology          
identified under paragraph 7#b71 a      
discussion of the plans of the          
,secretary to utilize the authorities of
 the ,secretary under section #bjc or   

#bji7;d77#a7 of title #ce1 ,united      
,states ,code1 to authorize a third     
party or ,federal agency to use the     
drug1 vaccine1 or medical technology4   
7b7 ,authorization of use ,not later    
than one year after the date of the     
enactment of this ,act1 the ,secretary  
of ,defense1 pursuant to section #bjc or
 #bji7;d77#a7 of title #ce1 ,united     
,states ,code1 shall authorize third    
parties or ,federal agencies to use not 
fewer than #aj drugs1 vaccines1 or      
medical technologies identified under   
subsection 7a77#b7 for the purpose of   
expanding military and civilian access  
to such drugs1 vaccines1 or             
technologies4  #c4 ,transparency in     
taxpayer-funded biomedical research     
investments by the ,department of       
,defense  7a7 ,in general ,the          
,secretary of ,defense shall-- 7#a7     
compile into a searchable database      
information relating to ,federal support
 7before or after the date of enactment 
of this ,act7 provided by the           

,department of ,defense or an entity    
acting on behalf of the ,department of  
,defense for biomedical research and    
development1 including drugs1 vaccines1 
and medical technologies2 and  7#b7 make
 such database available on the public  
website of the ,department of ,defense4 
7b7 ,covered information ,the           
information relating to ,federal support
 described in subsection 7a77#a7 shall  
include all contracts1 funding          
agreements1 licensing arrangements1     
other transactions1 and other           
arrangements entered into by1 or on     
behalf of1 the ,department of ,defense  
with respect to research and            
development1 manufacturing1 and         
distribution of a drug 7including a     
biological product71 cell or gene       
therapy1 medical device1 or other       
medical technology1 including the       
following3 7#a7 ,licensing agreements   
pursuant to section #bjg or #bji of     
title #ce1 ,united ,states ,code4  7#b7 
,cooperative research and development   

agreements and licensing agreements     
pursuant to section #cgaj;a of title    
#ae1 ,united ,states ,code4  7#c7       
,funding agreements1 as defined in      
section #bja of title #ce1 ,united      
,states ,code4  7#d7 ,transactions1     
contracts1 grants1 cooperative          
agreements1 other agreements1 and other 
arrangements entered into pursuant to   
the following3 7,a7 ,the ,public ,health
 ,service ,act 7#db ,u4,s4,c4 #bja et   
seq471 including sections #cja1 #cai,l1 
#dba1 and #dhj of such ,act 7#db        
,u4,s4,c4 #bda1 #bdg;d-#g;e1 #bhe;b-#c1 
#bhg;a74  7,b7 ,section #aje of the     
,national ,institutes of ,health ,reform
 ,act of #bjjf 7#db ,u4,s4,c4 #bhdn74   
7,c7 ,chapter #aci of title #aj1 ,united
 ,states ,code1 including sections      
#bceh1 #bcga1 #bcga;a1 #bcga;b1 and     
#bcgc4  7c7 ,information required       
,notwithstanding any other provision of 
law1 the ,secretary of ,defense shall   
include in the database under subsection
 7a71 with regard to each contract1     

funding agreement1 licensing agreement1 
other transaction1 or other arrangement 
described in subsection 7b71 at least   
the following information3 7#a7 ,the    
agency1 program1 institute1 or other    
entity of the ,department of ,defense   
providing the ,federal grant1           
cooperative agreement1 or other support4
  7#b7 ,the amount and period of        
,federal financial support with an      
itemized breakdown4  7#c7 ,other        
,federal nonfinancial support1 including
 the use of ,federal personnel1 ,federal
 facilities1 and ,federal equipment4    
7#d7 ,the grant number1 if applicable4  
7#e7 ,associated clinical trial data1   
upon trial completion4  7#f7 ,associated
 patents and patent applications1       
specifying-- 7,a7 any ,federal ownership
 in such patents and patent             
applications2  7,b7 the expiration date 
of such patents and filing dates of such
 patent applications2 and  7,c7 the     
numbers of such patents and patent      
applications4  7#g7 ,associated periods 

of marketing exclusivity under ,federal 
law and the durations of such periods4  
7#h7 ,the corporation1 nonprofit        
organization1 academic institution1     
person1 or other entity receiving the   
,federal support4  7#i7 ,any products   
7including repurposed products7         
approved1 authorized1 or cleared for    
marketing1 or for which marketing       
approval1 authorization1 or clearance is
 being sought1 the development of which 
was aided by ,federal support1          
including-- 7,a7 the names of such      
products2  7,b7 the prices of such      
products2 and  7,c7 the current and     
anticipated manufacturing capacity to   
produce such products4  7#aj7 ,the full 
terms of the contract1 funding          
agreement1 licensing agreement1 other   
transaction1 or other arrangement       
described in subsection 7b74  7d7       
,format of information ,the database    
under subsection 7a7 shall be-- 7#a7    
searchable and filterable according to  
the categories of information described 

in subsection 7c72 and  7#b7 presented  
in a user-friendly format4  7e7 ,timing 
,the database under subsection 7a7 shall
 be-- 7#a7 made publicly available not  
later than one month after the date of  
the enactment of this ,act2 and  7#b7   
updated not less frequently than once   
every two weeks4  7f7 ,disclosure  7#a7 
,in general ,notwithstanding any other  
provision of law1 to the extent         
necessary for the ,secretary of ,defense
 to carry out this section1 the         
,secretary may require entities         
receiving ,federal support described in 
subsection 7a77#a7 to disclose to the   
,secretary any information relating to  
such ,federal support and required to be
 included in the database under         
subsection 7a74  7#b7 ,intermediary     
cooperation  7,a7 ,in general ,any      
arrangement entered into by the         
,department of ,defense with an entity  
providing for such entity to enter into 
contracts1 licensing agreements1 grants1
 other transactions1 or other           

arrangements with third parties on      
behalf of the ,department shall require 
such entity to disclose in a timely     
manner any information necessary for the
 ,department to fulfill its duties under
 this section4  7,b7 ,existing          
arrangements ,with respect to any       
arrangement described in subparagraph   
7,a7 with an entity in place as of the  
date of the enactment of this ,act1 the 
,secretary of ,defense may require the  
entity to disclose to the ,secretary any
 information required to be included in 
the database under subsection 7a74  7#c7
 ,penalty for nondisclosure ,if an      
entity that is required to disclose     
information pursuant to paragraph 7#a7  
or 7#b7 fails to disclose such          
information by the date that is two     
weeks after the date on which the       
,secretary of ,defense requests such    
information1 or by such reasonable      
deadline as the ,secretary may specify1 
whichever is sooner1 then such entity   
shall be liable to the ,united ,states  

for a civil penalty in an amount not to 
exceed #aj1jjj for each day on which    
such failure continues4